anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: There is a difference in the incidence of spontaneous subarachnoid hemorrhage (SAH) between sexes, with the majority of cases occurring in female patients. Although this phenomenon has been studied from a medical perspective, the reasons for the predominance of female cases are still unclear. Non-medical factors, such as a patient's socioeconomic situation, can differ between female and male patients, with health implications. The aim of the study was to identify socioeconomic profiles for both sexes that may be vulnerable to developing SAH. This information could potentially be used for active preventive health efforts.
METHODS: This study was based on a 7-year consecutive cohort of 890 patients with SAH treated at Uppsala University Hospital, along with a sex- and age-matched 5:1 control group from Statistics Sweden. The collected information included demographic data, income that was analyzed through "earnings" (EAs), which is defined as the sum of income and other economic compensations related to work, and "disposable income" (DI), which is the net amount that an individual can use. Pension and sickness-related absence from work were measured using early pension (EP), old age pension (OAP), sickness absence (SA), and disability pension (DP). Univariate and multivariate analyses were used.
RESULTS: Among the women, the socioeconomic risk profile for SAH included lower education, unemployment, being registered as living single, residing in a sparsely populated municipality, and increased age. For the men, the risk profile included residing in a sparsely populated municipality and changes in civil status. Both women and men with SAH had lower EAs and DI compared to the controls. Notably, a significantly higher proportion of the women with SAH received DP compared to the controls.
CONCLUSION: Residing in a sparsely populated area was associated with an increased risk for SAH for both women and men. The women with SAH were more economically vulnerable, whereas the men faced a different type of vulnerability related to changes in civil status. We suggest that healthcare organizations use this information to identify individuals at risk and actively implement preventive measures according to stroke guidelines for both groups.
(See BOXED WARNING.)

Cases of life-threatening hepatic failure have been reported in patients treated with nefazodone hydrochloride tablets.

The reported rate in the United States is about 1 case of liver failure resulting in death or transplant per 250,000 to 300,000 patient-years of nefazodone treatment. This represents a rate of about 3 to 4 times the estimated background rate of liver failure. This rate is an underestimate because of under reporting, and the true risk could be considerably greater than this. A large cohort study of antidepressant users found no cases of liver failure leading to death or transplant among nefazodone users in about 30,000 patient-years of exposure. The spontaneous report data and the cohort study results provide estimates of the upper and lower limits of the risk of liver failure in nefazodone-treated patients, but are not capable of providing a precise risk estimate.

The time to liver injury for the reported liver failure cases resulting in death or transplant generally ranged from 2 weeks to 6 months on nefazodone therapy. Although some reports described dark urine and nonspecific prodromal symptoms (e.g., anorexia, malaise, and gastrointestinal symptoms), other reports did not describe the onset of clear prodromal symptoms prior to the onset of jaundice.

The physician may consider the value of liver function testing. Periodic serum transaminase testing has not been proven to prevent serious injury but it is generally believed that early detection of drug-induced hepatic injury along with immediate withdrawal of the suspect drug enhances the likelihood for recovery.

Patients should be advised to be alert for signs and symptoms of liver dysfunction (jaundice, anorexia, gastrointestinal complaints, malaise, etc.) and to report them to their doctor immediately if they occur. Ongoing clinical assessment of patients should govern physician interventions, including diagnostic evaluations and treatment.

Nefazodone should be discontinued if clinical signs or symptoms suggest liver failure (see PRECAUTIONS, Information for Patients). Patients who develop evidence of hepatocellular injury such as increased serum AST or serum ALT levels ≥  3 times the upper limit of NORMAL, while on nefazodone should be withdrawn from the drug. These patients should be presumed to be at increased risk for liver injury if nefazodone is reintroduced. Accordingly, such patients should not be considered for re-treatment.
PURPOSE: Delayed structural and functional recovery after a 20 km graded running race was analyzed with respect to the sex effect.
METHODS: Thirteen female and 14 male recreational runners completed the race and three test sessions: one before (PRE) and two after, once on Day 1 or 2 (D1-2) and then on Day 3 or 4 (D3-4). Muscle damage was assessed indirectly using ultrasonography to quantify changes in cross-sectional area (CSA) of 10 lower-limb muscles. Delayed onset of muscle soreness (DOMS) was assessed for three muscle groups. Functional recovery was quantified by kinetic analysis of a squat jump (SJ) and a drop jump (DJ) test performed on a sledge ergometer. Linear mixed models were used to assess control group reproducibility and recovery patterns according to sex.
RESULTS: Regardless of sex, DOMS peaked at D1-2 for all muscle groups and resolved at D3-4. CSA was increased in each muscle group until D3-4, especially in the semimembranosus muscle. A specific increase was found in the short head of the biceps femoris in women. Regardless of sex, SJ and DJ performances declined up to D3-4. Depending on the muscle, positive and/or negative correlations were found between structural and functional changes. Some of these were sex-specific.
CONCLUSION: Structural and functional recovery was incomplete in both sexes up to D3-4, although DOMS had disappeared. More emphasis should be placed on hamstring muscle recovery. Highlighting the intermuscular compensations that can occur during multi-joint testing tasks, the structural-functional relationships were either positive or negative, muscle- and sex-dependent.
It is disclosed herein that blockade of inter-alpha-trypsin inhibitor (IaI) prevents the development of airway hyperresponsiveness in animal models of asthma and chronic obstructive pulmonary disease. Provided herein are methods of treating an airway disease or disorder in a subject by administering to the subject a therapeutically effective amount of an inhibitor of IaI. Also provided is a method of preventing or reducing airway hyperresponsiveness in a subject by administering to the subject a therapeutically effective amount of an inhibitor of IaI. The IaI inhibitor can be any compound that inhibits the expression or activity of IaI or a gene encoding an IaI polypeptide. In some embodiments, the IaI inhibitor is administered locally to the airway of the subject in need of treatment. For example, the inhibitor can be administered by aerosol delivery, such as by using an inhaler or nebulizer.
PURPOSE:To prepare the titled tape, etc. which does not leave the adhesive on the skin after release, by applying a thin-film pressure-sensitive adhesive composed of a copolymer of an alkali or alkaline earth metal salt of an alpha,beta-unsaturated carboxylic acid and a (meth)acrylic acid ester and containing a drug component, to a substrate. CONSTITUTION:The titled adhesive tape or sheet for medical use is composed of a substrate (e.g. polyethylene film, etc.) and a pressure-sensitive adhesive layer composed of a copolymer of (A) an alpha,beta-unsaturated carboxylic acid alkali (ne earth) metal salt and (B) a (meth)acrylic acid ester and containing a drug component. Since the carboxyl group of the adhesive is converted to alkali or alkaline earth metal salt, the cohesive force of the adhesive becomes an adequate level, the residue of the adhesive to the skin is prevented, and the release of the drug component to the skin can be improved. Furthermore, there is no deterioration and discoloration with heat even if the drug component is unstable to acid. The above copolymer may contain other monomers as copolymerized components.
Atrial fibrillation is an abnormal heart beat that starts in the upper parts of the heart and can cause stroke or death, if untreated. In general, treatments are not very effective with frequent relapses of the abnormal heart beats. One explanation for the high relapse rate is that the treatments might not address the underlying cause of atrial fibrillation.

Recently, we have found that atrial fibrillation is associated with increased oxidative stress in a particular part of the top parts of the heart, the left atrial appendage (LAA). Oxidative stress is a condition where abnormal oxygen forms are produced. These forms harm the cells of the heart, causing them to beat abnormally. Also, the inside of the heart becomes sticky and more likely to form blood clots. These clots, when they travel to the head, are thought to be the main cause of stroke in this condition. We have found increased oxidative stress and increased evidence of blood clotting in pig and mouse models of atrial fibrillation. We would like to see if these same findings are present in the human LAA.

In this study, we will compare blood and tissue markers of oxidative stress between patients with and without atrial fibrillation who are scheduled to undergo cardiac surgery. It is the expectation that participants with atrial fibrillation will have more abnormal markers of atrial fibrillation. This study requires participants to be seen during their routine preoperative visit, undergo a history and physical examination, give blood only once, and allow use of their discarded LAA. This tissue is routinely removed at surgery because its removal is thought to reduce the risk of stroke in patients who develop atrial fibrillation after the surgery. This happens in up to 50% of patients, thus providing the desire to remove the LAA.
558,470. Linings for dentures. KINNEAR, R. A., DAVISON, J. W., and IMPERIAL CHEMICAL INDUSTRIES, Ltd. July 3, 1942, No. 9196. [Class 81 (ii)] Dentures are provided during fabrication, or subsequent to fabrication, with a resilient lining comprising a plasticised polymer or interpolymer of vinyl chloride containing between 20 and 70 per cent of a plasticiser which is preferably dibutyl phthalate. The plasticised polymer or interpolymer of vinyl chloride may be applied as a film or by deposition on the denture from a solution or aquaeous emulsion, but, in the preferred process, a plasticised polyvinyl chloride paste is used. Preferred interpolymers are obtained from organic compounds which contain the group CH<SP>2</SP>=C<, e.g. vinyl acetate, methacrylic esters and styrene, such organic compound constituting not more than 20 per cent by weight of the polyerisable mixture. In an example, a waxed-up model of a full denture was invested to the gum margin in white plaster in a flask and the wax removed by boiling water. The plaster model on which the wax denture was built was then coated with five layers of tin 9.003 inches thick. The other half of the plaster mould was coated with 1 part of water glass in 1 part of water, and allowed to dry. The mould was then packed with a monomer/polymer dough prepared from "Kallodent" 222 (Registered Trade Mark), the two halves of the flask being separated by sheets of "Cellophane" (Registered Trade Mark) during trial closures. When the mould was completely filled with dough, the excess was cut away, the cellophane and tin foil removed and the plaster model coated with sodium silicate solution and allowed to dry. A thick paste comprising 60 parts of polyvinyl chloride and 40 parts of dibutyl phthalate was then spread on the surface of the dough, the flask partially closed, clamped and pressed until fully closed. The clamped flask was then immersed in water at 30‹C. brought to boiling temperature in 20 minutes and left therein for 40 minutes. After cooling slowly to room temperature, the denture was deflasked and the lining trimmed with a sharp blade. In a further example, the lining was applied as a self-sustaining film of 45:55 polyvinyl chloride/dibutyl phthalate composition to the Kallodent dough in the flask prior to polymerisation. Specification 500,298, [Group IV], is referred to.
Patients receive GTI-2040 IV continuously on days 1-14, oral capecitabine twice daily on days 2-15, and oxaliplatin IV over 2 hours on day 2 of the first course. In all subsequent courses, capecitabine is administered on days 1-14, oxaliplatin is administered on day 1, and GTI-2040 is administered as in course 1. Courses repeat every 21 days in the absence of disease progression and unacceptable toxicity.
A method for treating patients with tuberculosis of lungs and bronchi comprises the simultaneous use of the artificial pneumothorax on the affected side and pneumoperitoneum in the combination with polychemotherapy. Upon admission to the hospital and then, the insufflation of air into the pleural and peritoneal cavities is performed once a week. The pneumothorax is extended to half of the pulmonary volume. When the adhesions are present, they areremoved under the control of videothoracoscope. The optimal volume of pneumoperitoneum extends up to the level of the anterior segment of the fourth rib. In addition, two antituberculous drugs are injected lymphotropically for two months. One drug is injected retrosternally at the site of the jugular recess. The second drug is administered retroxifoidally. The endobronchial sanitation of the tracheobronchial tree is performed once a week.
PCT No. PCT/JP94/02031 Sec. 371 Date Jul. 25, 1996 Sec. 102(e) Date Jul. 25, 1996 PCT Filed Dec. 2, 1994 PCT Pub. No. WO95/15751 PCT Pub. Date Jun. 15, 1995This invention provides an antipyretic analgesic preparation having good antipyretic and analgesic effects with reduced adverse effects such as gastrointestinal disorders. The object is achieved by providing a mixture composition containing ibuprofen and isopropylantipyrine. The ratio between them is preferably 5:1 to 1:5, more preferably 3:1 to 1:3, on the weight basis. Preferred dosage forms of the mixture composition are a three-layer tablet comprising an ibuprofen-containing first layer, an isopropylantipyrine-containing third layer, and a second layer composed of one or more inactive ingredients alone as provided between said first and third layers, a dry coated tablet internally having an ibuprofen- or isopropylantipyrine-containing core tablet, and so forth.
PROBLEM TO BE SOLVED: To obtain the subject inhibitor comprising the extracted essence of CHOUTOUKOU (a hook attached to the main axis of Uncaria rhynchophylla Miq. or Uncaria sinensis) as an active ingredient having inhibitory effect on melanogenesis, excellent beautifying effect, preventing and treating effect on stain/freckles caused by suntan, etc., useful as a cosmetic having high safety. SOLUTION: This melanogenesis inhibitor comprises the extracted essence of CHOUTOUKOU [a hook attached to the main axis of Uncaria rhynchophlla Miq. or Uncaria sinensis of (Rubiaceae)] as an active ingredient. The extraction, for example, is preferably carried out by extracting 30-150g of CHOUTOUKOU prepared by grinding after drying with 1l of ethanol under heating at 70 deg.C for 3 hours under reflux. The amount of CHOUTOUKOU is 0.005-0.1wt.% calculated as the dry weight of the extracted essence based on the whole amount of a skin preparation for external use.
FIELD: medicine, obstetrics. SUBSTANCE: to develop a regular delivery activity in risk-group pregnant women 200 mg Myphegin is introduced in case of delivery disorders. If the latter is not seen the same preparation should be reapplied in 24 h at the same dosage. Misoprostole should be injected if no delivery activity is observed 48 h after the last intake. EFFECT: advanced preparation to delivery process, decreased cases of complications associated with disorders in myometrium contracting activity. 2 ex
The invention discloses a poria cocos formula granule and a preparation method thereof. The preparation method comprises three parts, namely an extraction process, a drying process and a granulating process. The extraction process comprises the following steps of: respectively carrying out reflux extraction on coarse poria cocos powder and fine poria cocos powder by taking a sodium carbonate solution as an extraction solvent; merging filtrates, carrying out double-effect concentration, then carrying out high-density concentration, and uniformly mixing a high-density concentrated solution and fine residues to obtain a mixed solution A. The drying process comprises the following step of: carrying out microwave drying on the mixed solution A by adopting an intelligent static microwave vacuum drier to obtain a dry poria cocos extract. The granulating process comprises the following steps of: crushing and screening the dry poria cocos extract; totally mixing; carrying out dry granulation; packaging to obtain a finished product of the poria cocos formula granule. Every 1 gram of the poria cocos formula granules is equivalent to 5 grams of crude drugs. The preparation method disclosed by the invention can be used for solving the problem of low extraction yield of effective components of poria cocos, and can be used for drying by adopting a microwave drying technology, thus improving the drying efficiency. The preparation process is suitable for industrialized large-scale production.
PCT No. PCT/FR96/01511 Sec. 371 Date Apr. 13, 1998 Sec. 102(e) Date Apr. 13, 1998 PCT Filed Oct. 8, 1996 PCT Pub. No. WO97/13768 PCT Pub. Date Apr. 17, 1997Compounds derived from oxazolidin-2-one of formula (I) in which: R1 represents a hydrogen atom, an alkyl group, a hydroxyalkyl group, a fluoroalkyl group, a hydroxyfluoroalkyl group, a cyanoalkyl group, a substituted or unsubstituted phenyl group, a substituted or unsubstituted phenylmethyl group or an R3A- group in which R3 is a cycloalklyl or cyclooxyalkyl group which is unsubstituted or substituted by a hydroxyl group and A is a -CH2 or -CH2-CH2 radical, R2 represents a hydrogen atom or a methyl group, X represents an oxygen or sulphur atom or an NR4 group where R4 is an alkyl group or a hydrogen atom, and Z represents an oxygen atom or a -CH=CH or -CH2-CH2 group, their process of preparation and their applications in therapeutics.
OBJECTIVE: We leveraged an artificial intelligence deep-learning convolutional neural network (DL CNN) to detect calcified carotid artery atheromas (CCAAs) on cone beam computed tomography (CBCT) images.
STUDY DESIGN: We obtained 137 full-volume CBCT scans with previously diagnosed CCAAs. The DL model was trained on 170 single axial CBCT slices, 90 with extracranial CCAAs and 80 with intracranial CCAAs. A board-certified oral and maxillofacial radiologist confirmed the presence of each CCAA. Transfer learning through a U-Net-based CNN architecture was utilized. Data allocation was 60% training, 10% validation, and 30% testing. We determined the accuracy of the DL model in detecting CCAA by calculating the mean training and validation accuracy and the area under the receiver operating characteristic curve (AUC). We reserved 5 randomly selected unseen full CBCT volumes for final testing.
RESULTS: The mean training and validation accuracy of the model in detecting extracranial CCAAs was 92% and 82%, respectively, and the AUC was 0.84 with 1.0 sensitivity and 0.69 specificity. The mean training and validation accuracy in detecting intracranial CCAAs was 61% and 70%, respectively, and the AUC was 0.5 with 0.93 sensitivity and 0.08 specificity. Testing of full-volume scans yielded an AUC of 0.72 and 0.55 for extracranial and intracranial CCAAs, respectively.
CONCLUSION: Our DL model showed excellent discrimination in detecting extracranial CCAAs on axial CBCT images and acceptable discrimination on full-volumes but poor discrimination in detecting intracranial CCAAs, for which further research is required.
Adults (18 to 55 years)

The recommended starting dose of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules is 12.5 mg once daily in the morning upon awakening. Initial doses of 25 mg once daily may be considered for some patients. Dosage may be adjusted in increments of 12.5 mg no sooner than weekly, up to a maximum dose of 50 mg once daily, based on the therapeutic needs and response of the patient. Doses above 50 mg daily have shown no additional clinically meaningful benefit. 

Pediatric Patients (13 to 17 years) 

The recommended starting dose is 12.5 mg once daily in the morning upon awakening. Dosage may be adjusted in increments of 12.5 mg no sooner than weekly, up to a recommended maximum dose of 25 mg once daily. The dose should be individualized according to the needs and response of the patient. Doses higher than 25 mg have not been evaluated in clinical trials in pediatric patients.
It is intended to provide a base for a cosmetic comprising a nonionic resin, which is soluble in water, alcohol and liquefied petroleum gas (LPG), facilitates the adjustment of a property as a base for a cosmetic, and is useful particularly as a base for a hair cosmetic. The base for a cosmetic according to the invention is a nonionic resin composed of a polymer of an ethylenic unsaturated monomer component (A) including a nonionic unsaturated monomer (a). In the nonionic unsaturated monomer (a), N,N-dimethylacrylamide (a1) represented by the following chemical formula (1) is included as an essential component. This base for a cosmetic isa nonionic resin, therefore, a problem of lack of compatibility even if it is used with another resin is unlikely to occur. Further, it shows a favorable solubility in various types of solvents for the base. The solubility of the base for a cosmetic in various types of solvents, properties as the base for a cosmetic such as a glass transition point or adhesiveness are easily adjusted.
The initial prescription and renewal of the medication order beyond 20 milliliters of the suspension should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. If signs and symptoms fail to improve after two days, the patient should be re-evaluated. 

The possibility of fungal infections of the cornea should be considered after prolonged corticosteroid dosing. Use with caution in patients with severe dry eye. Fungal cultures should be taken when appropriate. 

The p-aminobenzoic acid present in purulent exudates competes with sulfonamides and can reduce their effectiveness.